{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective","description":"The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, &quot;Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective,&quot; expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss:   Importance of JAK\/STAT signaling in AD and the role of JAK inhibition in the future of dermatology   Long-term safety of topical therapies for chronic AD   Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial   Shifting the paradigm of topical AD care across patient populations   ","author_name":"DermDocs","author_url":"http:\/\/dermdocs.libsyn.com\/website","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/38373800\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/193510635"}